ArvinasARVN
About: Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Employees: 430
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
313% more call options, than puts
Call options by funds: $24.7M | Put options by funds: $5.98M
42% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 52
33% more funds holding in top 10
Funds holding in top 10: 6 [Q1] → 8 (+2) [Q2]
14% more capital invested
Capital invested by funds: $451M [Q1] → $513M (+$61.1M) [Q2]
1.88% more ownership
Funds ownership: 93.19% [Q1] → 95.07% (+1.88%) [Q2]
4% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 51
1% less funds holding
Funds holding: 213 [Q1] → 210 (-3) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Andrew S. Fein | 139%upside $18 | Buy Maintained | 7 Aug 2025 |
Wells Fargo Derek Archila | 112%upside $16 | Overweight Maintained | 7 Aug 2025 |
Guggenheim Michael Schmidt | 99%upside $15 | Buy Maintained | 7 Aug 2025 |
Leerink Partners Andrew Berens | 19%upside $9 | Market Perform Downgraded | 2 Jun 2025 |
Financial journalist opinion
Based on 5 articles about ARVN published over the past 30 days
